Evaluation of Ketamine as Sedative Agent in Endoscopic Retrograde Cholangiopancreatography (ERCP)

Trial statusRecruiting
Trial phasePhase 4
Trial typeInterventional
Biological sexAll
Age16+
SponsorUniversiti Kebangsaan Malaysia Medical Centre

About this trial

This is a study evaluating the usage of Ketamine as sedative agent in ERCP. The usage of Ketamine will be compared to the standard sedation in our center, which is Midazolam in combination with Pethidine as analgesia.

Eligibility criteria

Qualifiers

Malaysian citizens of who is able to give valid consent

Patient planned for ERCP (either emergency or elective)

Disqualifiers

Known hypersensitivity towards Ketamine or Midazolam

Patient refusal to participate or unable to give consent

Increased intracranial pressure, acute stroke (<3 months), intracranial haemorrhage (<3 months)

Uncontrolled hypertension (BP>160/100) and tachycardia (Heart rate >120)

Trial design

Treatments tested in this trial

  • Ketamine Hydrochloride

Treatment groups

140 Participants
are divided into 2 treatment groups

Locations

1

Map coordinates are unavailable for these locations. Locations are shown below instead.

University Kebangsaan Malaysia Medical centerRecruiting56000, Bandar Tun Razak, Kuala LumpurMalaysiaMalaysia